ArticleBMJ open2026
Healthcare providers' perspectives on factors influencing treatment choices for HIV-associated cryptococcal meningitis in Tanzania: a qualitative exploratory study in two regional referral hospitals.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo explore healthcare providers' perspectives on factors influencing treatment selection for HIV-associated cryptococcal meningitis (CM) in Tanzania.
designA hospital-based qualitative exploratory study.
settingDodoma and Singida Regions, Tanzania.
participants17 medical doctors, nurses and pharmacists working in the medical wards were purposely selected based on their clinical experience in managing adult patients with HIV-associated CM.
resultsTreatment choices were influenced by four major themes: (1) guideline awareness and transition from outdated practices; (2) provider experience, confidence and perceived competency; (3) recurrent stock-outs of amphotericin B, flucytosine and essential electrolyte supplements; and (4) patient-level financial barriers affecting access to monitoring and supportive care.
conclusionHIV-associated CM treatment is shaped by healthcare providers, drug availability and patient-related factors. Targeted efforts to strengthen guideline dissemination, ensure uninterrupted antifungal supply and build provider capacity for safe amphotericin B use are crucial for improving CM outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.